Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Tsalikian

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Diabetes Care|February 11, 2021
Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal StudyNelly Mauras, Bruce Buckingham, Neil H White, et al.
Diabetes|December 10, 2014
Longitudinal assessment of neuroanatomical and cognitive differences in young children with type 1 diabetes: association with hyperglycemiaNelly Mauras, Paul Mazaika, Bruce Buckingham, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
The New England Journal of Medicine|September 10, 2008
Continuous glucose monitoring and intensive treatment of type 1 diabetes, William V Tamborlane, Roy W Beck, et al.
Diabetes Care|May 12, 2009
The effect of continuous glucose monitoring in well-controlled type 1 diabetes, Roy W Beck, Irl B Hirsch, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Diabetes Care|February 11, 2021
Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal StudyNelly Mauras, Bruce Buckingham, Neil H White, et al.
Diabetes|December 10, 2014
Longitudinal assessment of neuroanatomical and cognitive differences in young children with type 1 diabetes: association with hyperglycemiaNelly Mauras, Paul Mazaika, Bruce Buckingham, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
The New England Journal of Medicine|September 10, 2008
Continuous glucose monitoring and intensive treatment of type 1 diabetes, William V Tamborlane, Roy W Beck, et al.
Diabetes Care|May 12, 2009
The effect of continuous glucose monitoring in well-controlled type 1 diabetes, Roy W Beck, Irl B Hirsch, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Pageof 6